Patents by Inventor Monica Michelle GOSS

Monica Michelle GOSS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical formulations comprising anti-RANKL antibodies and an aromatic amino acid comprising a phenyl or an indole
    Patent number: 11873343
    Abstract: Disclosed herein are aqueous pharmaceutical formulations comprising denosumab or another human anti-RANKL monoclonal antibody or portion thereof, and characteristics of pH, buffer systems, and amino acid aggregation inhibitors. Also disclosed are presentation of the formulation for use, e.g. in a single-use vial, single-use syringe, or glass container, methods of using the formulations and articles for preventing or treating diseases, and related kits.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: January 16, 2024
    Assignee: AMGEN INC.
    Inventors: Stephen Robert Brych, Lyanne M. Wong, Jaymille Fallon, Monica Michelle Goss, Jian Hua Gu, Pavan K. Ghattyvenkatakrishna
  • VEGFR-FC FUSION PROTEIN FORMULATIONS
    Publication number: 20230025418
    Abstract: VEGFR-Fc fusion protein formulations and methods of making using such formulations are provided herein. In one embodiment, the formulation is an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the VEGFR-Fc fusion protein is aflibercept.
    Type: Application
    Filed: September 14, 2022
    Publication date: January 26, 2023
    Applicant: Amgen Inc.
    Inventors: Yael WEXLER-COHEN, Robert Matthew FESINMEYER, Monica Michelle GOSS, Sekhar KANAPURAM, Rahul Rajan KAUSHIK, Sai Chakradhar PADALA
  • FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME
    Publication number: 20220143181
    Abstract: Disclosed herein are aqueous pharmaceutical formulations comprising denosumab or another human anti-RANKL monoclonal antibody or portion thereof, and characteristics of pH, buffer systems, and amino acid aggregation inhibitors. Also disclosed are presentation of the formulation for use, e.g. in a single-use vial, single-use syringe, or glass container, methods of using the formulations and articles for preventing or treating diseases, and related kits.
    Type: Application
    Filed: November 18, 2021
    Publication date: May 12, 2022
    Applicant: AMGEN INC.
    Inventors: Stephen Robert BRYCH, Lyanne M. WONG, Jaymille FALLON, Monica Michelle GOSS, Jian Hua GU, Pavan K. GHATTYVENKATAKRISHNA
  • Formulations comprising human anti-RANKL monoclonal antibodies, and methods of using the same
    Patent number: 11192952
    Abstract: Disclosed herein are aqueous pharmaceutical formulations comprising denosumab or another human anti-RANKL monoclonal antibody or portion thereof, and characteristics of pH, buffer systems, and amino acid aggregation inhibitors. Also disclosed are presentation of the formulation for use, e.g. in a single-use vial, single-use syringe, or glass container, methods of using the formulations and articles for preventing or treating diseases, and related kits.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: December 7, 2021
    Assignee: Amgen Inc.
    Inventors: Stephen Robert Brych, Lyanne M. Wong, Jaymille Fallon, Monica Michelle Goss, Jian Hua Gu, Pavan Ghattyvenkatakrishna
  • FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME
    Publication number: 20200354463
    Abstract: Disclosed herein are aqueous pharmaceutical formulations comprising denosumab or another human anti-RANKL monoclonal antibody or portion thereof, and characteristics of pH, buffer systems, and amino acid aggregation inhibitors. Also disclosed are presentation of the formulation for use, e.g. in a single-use vial, single-use syringe, or glass container, methods of using the formulations and articles for preventing or treating diseases, and related kits.
    Type: Application
    Filed: April 27, 2018
    Publication date: November 12, 2020
    Inventors: Stephen Robert Brych, Lyanne M. Wong, Jaymille Fallon, Monica Michelle Goss, Jian Hua Gu, Pavan Ghattyvenkatakrishna
  • VEGFR-FC FUSION PROTEIN FORMULATIONS
    Publication number: 20200255496
    Abstract: VEGFR-Fc fusion protein formulations and methods of making using such formulations are provided herein. In one embodiment, the formulation is an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the VEG-FR-Fc fusion protein is aflibercept.
    Type: Application
    Filed: September 17, 2018
    Publication date: August 13, 2020
    Applicant: AMGEN INC.
    Inventors: Yael WEXLER-COHEN, Robert Matthew FESINMEYER, Monica Michelle GOSS, Sekhar KANAPURAM, Rahul Rajan KAUSHIK, Sai Chakradhar PADALA